- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00450866
Epothilone B in Treating Patients With CNS Metastases From Breast Cancer
Phase II Trial of Patupilone in Patients With Brain Metastases From Breast Cancer
RATIONALE: Drugs used in chemotherapy, such as epothilone B, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
PURPOSE: This phase II trial is studying how well epothilone B works in treating patients with CNS metastases from breast cancer.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
OBJECTIVES:
Primary
- Determine the 3-month CNS-progression free survival of patients with CNS metastases secondary to breast cancer treated with epothilone B.
Secondary
- Determine the toxicity of this drug in these patients.
- Determine the CNS response rate and duration of CNS response in patients treated with this drug.
- Determine the systemic disease response rate and duration of systemic response in patients treated with this drug.
- Determine the overall survival of patients treated with this drug.
OUTLINE: This is a multicenter, open-label study.
Patients receive epothilone B IV over 20 minutes on day 1. Courses repeat every 21 days in the absence of disease progression, satisfactory response, or unacceptable toxicity.
After completion of study treatment, patients are followed periodically.
PROJECTED ACCRUAL: A total of 55 patients will be accrued for this study.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02114
- Massachusetts General Hospital
-
-
Michigan
-
Ann Arbor, Michigan, United States, 48109
- University of Michigan Comprehensive Cancer Center
-
-
New York
-
New York, New York, United States, 10065
- Memorial Sloan-Kettering Cancer Center
-
-
Ohio
-
Cleveland, Ohio, United States, 44195
- Cleveland Clinic Taussig Cancer institute, Case Comprehensive Cancer Center
-
Cleveland, Ohio, United States, 44106-5065
- Case Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
DISEASE CHARACTERISTICS:
- Histologically or cytologically confirmed carcinoma of the breast
CNS metastases (i.e., brain parenchymal lesions and/or leptomeningeal disease), meeting 1 of the following criteria:
Recurrent or progressive CNS metastases after whole brain radiotherapy
- If only evaluable site of CNS progression has been previously treated with stereotactic radiosurgery, radiation necrosis must be excluded by radiographic (e.g., positron emission tomography scan or magnetic resonance spectroscopy) or histologic assessment
- Newly diagnosed, untreated, asymptomatic brain or leptomeningeal metastases
- Patient must be neurologically stable, as demonstrated by a stable dose of steroids and anticonvulsants for ≥ 1 week prior to obtaining baseline gadolinium-enhanced MRI of the brain and/or ≥ 1 week prior to beginning study treatment
- No CNS complications requiring urgent neurosurgical intervention (e.g., resection or shunt placement)
- Hormone receptor status not specified
PATIENT CHARACTERISTICS:
- Male or female
- Menopausal status not specified
- Karnofsky performance status 60-100%
- Life expectancy ≥ 3 months
- Absolute neutrophil count > 1,500/mm^3
- Hemoglobin > 9.0 g/dL
- Platelet count > 100,000/mm^3 (red blood cell transfusion and repeat evaluation allowed)
- Bilirubin < 1.5 times upper limit of normal (ULN)
- AST and ALT < 2.5 times ULN
- Alkaline phosphatase < 2.5 times ULN
- Creatinine < 1.5 times ULN
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception during and for 3 months after completion of study therapy
- No known hypersensitivity to epothilones
- No peripheral neuropathy > grade 1
No unresolved diarrhea within the past 7 days
- Grade 0 diarrhea required at study entry
- No concurrent serious medical illness (e.g., HIV positivity or active hepatitis B or C)
- No severe cardiac insufficiency (e.g., New York Heart Association class III-IV heart disease) with uncontrolled and/or unstable cardiac or coronary artery disease
- No active or suspected acute or chronic uncontrolled infection, including abscess or fistulae
- No other malignancy within the past 3 years except curatively treated nonmelanoma skin cancer, prostate cancer, or carcinoma in situ of the cervix
- No history of noncompliance to medical regimens or inability or unwillingness to return for all scheduled visits
No contraindications to MRI, including any of the following:
- Pacemaker
- Ferromagnetic implants
- Claustrophobia
- Extreme obesity
PRIOR CONCURRENT THERAPY:
- See Disease Characteristics
- More than 2 weeks since prior noncytotoxic drugs (e.g., small molecule-targeted drugs) and recovered
- More than 3 weeks since prior cytotoxic chemotherapy (6 weeks for nitrosoureas or mitomycin C) and recovered
- More than 3 weeks since prior intracranial surgery and recovered
- More than 4 weeks since prior radiotherapy and recovered
- More than 4 weeks since prior major surgery
- More than 28 days since prior investigational compounds or drugs
- No prior epothilones
- No concurrent known diarrheagenic agents
- No other concurrent anticancer agents, including investigational agents, biological agents, or chemotherapy
- No other concurrent experimental therapies
- Concurrent hormone therapy and/or trastuzumab (Herceptin®) allowed
No concurrent Coumadin® or other agents containing warfarin
- Low dose Coumadin® (≤ 1 mg) for prophylactic maintenance of indwelling lines or ports allowed
No concurrent radiotherapy for central metastases (e.g., vertebral or mediastinal metastases)
- Concurrent radiotherapy for local peripheral metastases not being used as marker lesions allowed
- No concurrent prophylactic hematopoietic growth factors during course 1
- No concurrent herbal or nontraditional medications
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Epothilone B
|
Patupilone will be administered as a single intravenous infusion over 20 minutes, once every 3 weeks.
Patupilone will be administered at a dose of 10 mg/m2 (q3weeks) with actual body weight.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Central Nervous System (CNS) Progression-free Survival(PFS)
Time Frame: 3 months after treatment
|
The number of patients that are documented to have progression free survival at 3 months after treatment. Progression free is define as <25% increase in tumor area. PFS will be measured from the date of entry into the trial to the date of documented progression of brain metastases or death. |
3 months after treatment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Toxicity as Measured by NCI CTCAE v3.0
Time Frame: 3 months after treatment
|
Percent of patients that experience the most common grade 3 and above toxicities possibly related to study drug - to be measured using the NCI Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 3.0.
|
3 months after treatment
|
CNS Response Rate, for Measurable Disease Will be Assessed by the Modified McDonald Criteria
Time Frame: 3 months after treatment
|
Complete Response (CR): the circumstance when the tumor is no longer seen by neuroimaging Partial Response (PR): Decrease of >50% in the product of two diameters Stable Disease (SD): the circumstance when the scan shows no change.
Progression (P): a > 25% increase in tumor area (two diameters)
|
3 months after treatment
|
Systemic Disease Response Rate for Measurable Disease Will be Assessed by the Modified McDonald Criteria
Time Frame: 3 months after treatment
|
Complete Response (CR): the circumstance when the tumor is no longer seen by neuroimaging Partial Response (PR): Decrease of >50% in the product of two diameters Stable Disease (SD): the circumstance when the scan shows no change.
Progression (P): a > 25% increase in tumor area (two diameters)
|
3 months after treatment
|
Overall Survival
Time Frame: 48 months from start of study
|
Median time (months) that patients survived during the duration of the study.
|
48 months from start of study
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: David M. Peereboom, MD, Cleveland Clinic Taussig Cancer institute, Case Comprehensive Cancer Center
- Principal Investigator: Joseph Baar, MD, Case Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- CASE5106
- P30CA043703 (U.S. NIH Grant/Contract)
- MSKCC-07036 (Other Identifier: MSKCC)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Cancer
-
Northwestern UniversityEisai Inc.UnknownMale Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative...United States
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI); Rutgers Cancer Institute of New JerseyActive, not recruitingStage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedMale Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)WithdrawnStage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer
-
University of WashingtonTerminatedBreast Cancer | Breast Cancer Stage I | Breast Cancer Stage II | Breast Cancer Stage III | Breast Cancer Stage IIB | Breast Cancer Stage IIA | Breast Cancer Stage IIIA | Breast Cancer Stage IIIB | Breast Cancer Stage IIIcUnited States
-
CelgeneCompletedBreast Cancer | Metastatic Breast Cancer | Stage IV Breast Cancer | Triple-negative Breast Cancer | Recurrent Breast Cancer | Breast Tumor | Cancer of the Breast | Triple-negative Metastatic Breast Cancer | Estrogen Receptor- Negative Breast Cancer | HER2- Negative Breast Cancer | Progesterone Receptor- Negative...United States, United Kingdom, Italy, Germany, Spain, Canada, Portugal, Australia, Austria, Greece, Brazil, France
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedHER2-positive Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Estrogen Receptor-negative Breast Cancer | Estrogen Receptor-positive Breast Cancer | Progesterone Receptor-negative Breast Cancer | Progesterone Receptor-positive Breast...United States
-
University of California, IrvineNational Cancer Institute (NCI); National Institutes of Health (NIH)CompletedBreast Cancer | HER2-positive Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer | HER2-negative Breast CancerUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-positive Breast CancerUnited States
Clinical Trials on epothilone B
-
Novartis PharmaceuticalsCompleted
-
Novartis PharmaceuticalsCompleted
-
Novartis PharmaceuticalsCompleted
-
Novartis PharmaceuticalsCompletedColorectal Neoplasms | Colonic NeoplasmsUnited States
-
Novartis PharmaceuticalsCompleted
-
Novartis PharmaceuticalsCompletedOvarian Neoplasms | Fallopian Tube Neoplasms | Peritoneal NeoplasmsNetherlands, Canada, United States, Slovakia, United Kingdom
-
Sidney Kimmel Cancer Center at Thomas Jefferson...Novartis PharmaceuticalsCompletedHead and Neck Neoplasms | Central Nervous System NeoplasmsUnited States
-
Novartis PharmaceuticalsCompleted
-
National Cancer Institute (NCI)Gynecologic Oncology GroupCompletedRecurrent Endometrial Carcinoma | Endometrial Adenocarcinoma | Stage IV Endometrial CarcinomaUnited States
-
National Cancer Institute (NCI)CompletedMetastatic Transitional Cell Cancer of the Renal Pelvis and Ureter | Recurrent Bladder Cancer | Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter | Regional Transitional Cell Cancer of the Renal Pelvis and Ureter | Stage III Bladder Cancer | Stage IV Bladder Cancer | Transitional... and other conditionsUnited States